XML 65 R34.htm IDEA: XBRL DOCUMENT v3.25.1
SHAREHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2024
Stockholders' Equity Note [Abstract]  
Schedule of Stock by Class
Year ended December 31,
202420232022
Cost of revenues$14,146 $15,013 $17,810 
Research and development126,462 119,482 120,581 
Selling and marketing38,755 41,277 38,714 
General and administrative61,358 48,853 59,731 
Total share-based compensation expense$240,721$224,625$236,836
Share-based Payment Arrangement, Option, Activity
Number
of
options
Weighted
average
exercise
price
Weighted
Average
remaining contractual term
(in years)
Aggregate
intrinsic value
Balance at December 31, 20233,956,056$97.93 4.93$167,822 
Granted74,814 116.94 
Exercised(828,721)60.41 
Forfeited(36,516)127.07 
Balance at December 31, 20243,165,633107.86 4.38355,730
Exercisable at December 31, 20242,937,959105.47 4.13337,444
Vested and expected to vest at December 31, 20243,158,931$107.82 4.37$355,108
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
Year ended December 31,
202420232022
Expected volatility
58.16%-59.04%
59.91%
52.75%-59.08%
Expected dividends0%0%0%
Expected term (in years)
5.10-5.16
5.05
4.93-5.03
Risk free rate
4.08%-4.45%
4.11%
1.81%-4.34%

The following table set forth the parameters used in computation of the ESPP for the years ended December 31, 2024, 2023 and 2022:

Year ended December 31,
202420232022
Expected volatility
34.52%-43.55%
50.40%-67.14%
65.00%-77.20%
Expected dividends0%0%0%
Expected term (in years)0.50.50.5
Risk free rate
4.84%-5.27%
5.17%-5.47%
0.60%-3.34%
Share-Based Compensation Arrangement By Share-Based Payment Award, Option Summary Of Option Data
Year ended December 31,
202420232022
Weighted-average grant date fair value of options granted, per option$78.15 $84.97 $49.14 
Total intrinsic value of the options exercised$102,390 $19,450 $11,843 
Share-based Payment Arrangement, Option, Exercise Price Range
Exercise price
(range)
Options outstanding
as of
December
31, 2024
Weighted average remaining
contractual term
Options exercisable
as of December
31, 2024
Weighted average remaining
contractual term
(years)(years)
0-20.9424,4845.1718,5444.01
20.95-30.66356,9621.12356,9621.12
30.67-55.86396,5652.12396,5652.12
55.87-61.95470,9013.12470,9013.12
61.96-100.6225,7226.06216,7816.03
100.61-102.67408,8254.12408,8254.12
102.68-138.62463,5587.28273,6986.94
138.63-143.13408,2545.14408,2545.14
143.14-260.88388,7256.09365,7926.09
260.89-353.0921,6376.0121,6376.01
3,165,6334.382,937,9594.13
Schedule of Nonvested Restricted Stock Units Activity
Number
of
shares
Weighted
average
grant date
fair value per share
Unvested as of December 31, 20233,211,421 $105.77 
Granted1,939,025 136.21
Vested(1,463,226)120.23
Forfeited (343,516)110.67
Unvested as of December 31, 20243,343,704 $116.59 
Schedule of Total Accumulated Other Comprehensive Loss, Net
Year ended December 31, 2024
Unrealized gain (losses) on marketable securitiesUnrealized gain (losses) on cash flow hedgesTotal
Beginning balance, net$(3,096)$7,288$4,192
Other comprehensive income (loss) before reclassifications, net2,780(7,176)(4,396)
Amounts reclassified from accumulated other comprehensive income (loss) to earnings:
Cost of revenues360360
Research and development, net4,4754,475
Selling and marketing1,5981,598
General and administrative1,0231,023
Financial expenses, net(10)(10)
Total accumulated other comprehensive income (loss), net$(326)$7,568 $7,242 
NOTE 12:-    SHAREHOLDERS' EQUITY (Cont.)

Year ended December 31, 2023
Unrealized gain (losses) on marketable securitiesUnrealized gain (losses) on cash flow hedgesTotal
Beginning balance, net $(11,689)$(21,766)$(33,455)
Other comprehensive income (loss) before reclassifications, net5,645(12,556)(6,911)
Amounts reclassified from accumulated other comprehensive income (loss) to earnings:
Cost of revenues1,9931,993
Research and development, net25,16025,160
Selling and marketing8,9978,997
General and administrative5,4605,460
Financial income, net2,9482,948
Total accumulated other comprehensive income (loss), net$(3,096)$7,288$4,192